A Reversal for Cytori Therapeutics, Inc. (CYTX) Is Not Near. The Stock Reaches 1 Year Low Today

June 17, 2018 - By Marie Mckinney

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Logo

The stock of Cytori Therapeutics, Inc. (NASDAQ:CYTX) hit a new 52-week low and has $1.83 target or 6.00 % below today’s $1.95 share price. The 8 months bearish chart indicates high risk for the $12.00M company. The 1-year low was reported on Jun, 17 by Barchart.com. If the $1.83 price target is reached, the company will be worth $720,000 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 6.25% or $0.13 during the last trading session, reaching $1.95. About 144,981 shares traded. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 76.31% since June 17, 2017 and is downtrending. It has underperformed by 88.88% the S&P500.

Analysts await Cytori Therapeutics, Inc. (NASDAQ:CYTX) to report earnings on August, 9. They expect $-0.50 EPS, up 72.22 % or $1.30 from last year’s $-1.8 per share. After $-0.70 actual EPS reported by Cytori Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -28.57 % EPS growth.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Coverage

Among 3 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cytori Therapeutics had 3 analyst reports since February 22, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, May 7. Maxim Group maintained the shares of CYTX in report on Friday, March 9 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 22 by Laidlaw.

More notable recent Cytori Therapeutics, Inc. (NASDAQ:CYTX) news were published by: Seekingalpha.com which released: “Cytori details subscription rights offering” on June 12, 2018, also Streetinsider.com with their article: “B.Riley/FBR Remains Bullish on Cytori Therapeutics (CYTX)” published on May 29, 2018, Benzinga.com published: “45 Biggest Movers From Yesterday” on June 08, 2018. More interesting news about Cytori Therapeutics, Inc. (NASDAQ:CYTX) were released by: Benzinga.com and their article: “40 Biggest Movers From Yesterday” published on June 15, 2018 as well as Nasdaq.com‘s news article titled: “Cytori Therapeutic’s common stock to begin trading on adjusted basis on May 24, following one-for-ten reverse split” with publication date: May 23, 2018.

Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company has market cap of $12.00 million. The firm primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It currently has negative earnings. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: